Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01060982
Other study ID # HIFU/F/12.02
Secondary ID
Status Completed
Phase N/A
First received February 1, 2010
Last updated May 5, 2014
Start date February 2010
Est. completion date January 2013

Study information

Verified date May 2014
Source Theraclion
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

This study is a multicentre, open, uncontrolled trial for the observation of histological changes in parathyroid adenomas following high intensity focused ultrasound (HIFU).

This study will be conducted in France in 10 patients with primary hyperparathyroidism scheduled for a parathyroidectomy. The patient will receive an HIFU treatment in the center of the adenoma before the surgery.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patient 18 years or older.

- Patients with diagnosed primary hyperparathyroidism (clinical symptoms and/or biochemical disturbances) scheduled for parathyroidectomy.

- One diseased parathyroid gland, visualized by ultrasonography.

- The diseased targeted parathyroid gland accessible for HIFU treatment (anonymised ultrasonographic images to be sent to the sponsor's technical team for validation).

- Normal pretreatment nasofibroscopy.

- Voluntary signed informed consent.

Exclusion Criteria:

- Inaccessibility or high risk of targeting neighbouring structures, as evidenced by:

- Targeted area located less than 2 mm laterally from the oesophagus or the carotid artery

- Targeted area located less than 3 mm laterally from the trachea,

- Significant hyperechoic area with a posterior shadow located less than 10 mm behind the targeted area (behind to be understood as posterior to the targeted area in the direction of the HIFU beam)

- Investigator appreciation of any abnormal blood test that could contraindicate treatment with HIFU (bleeding abnormalities)

- Known spondylitis of the neck vertebrae

- Head and/or neck disease that prevents hyperextension of neck.

- Known history of parathyroid or other neoplasias in the neck region.

- History of neck irradiation

- Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit

- Pregnant or lactating woman.

- Female patient of childbearing age if not having a suitable contraception method.

- Patients who have received any investigational drug or device within the last 15 days and/or patients who are currently participating in another clinical trial.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Intervention

Device:
Ultrasonic ablation device
One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient

Locations

Country Name City State
France Cochin Hospital Paris
France Hôpital Privé des Peupliers Paris

Sponsors (1)

Lead Sponsor Collaborator
Theraclion

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Histology of excised gland. After surgery performed the same day as High intensity focused ultrasound treatment No